Astrazeneca (AZN) Gross Margin (2009 - 2026)
Astrazeneca (AZN) posted quarterly Gross Margin of 16376.62% for Q1 2026, up 104284.0% year-over-year from N/an in Q1 2025, and down 92.07% on a QoQ basis from 206416.67% in Q4 2025.
Astrazeneca (AZN) Gross Margin (2009 - 2026) Analysis & Trends
Astrazeneca (AZN) has reported Gross Margin for 18 consecutive years, with 16376.62% the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Margin rose 104284.0% year-over-year to 16376.62%; the TTM figure through Mar 2026 stood at 48400.98% (up 4370014.0% YoY), while the FY2025 annual figure was 81.9%, down 467065.0% from the prior year.
- Gross Margin came in at 16376.62% for Q1 2026 at Astrazeneca, down from 206416.67% in the prior quarter.
- The five-year high for Gross Margin was 268875.0% in Q2 2024, with the low at 1492.76% in Q4 2024.
- Average Gross Margin over 5 years is 66775.58%, with a median of 16376.62% recorded in 2026.
- Across the five-year window, Gross Margin sank 25420052 bps in 2023 and jumped 26397552 bps in 2024, its largest moves.
- Year by year, Gross Margin stood at 5257.59% in 2022, then tumbled by 33 bps to 3507.58% in 2023, then sank by 57 bps to 1492.76% in 2024, then jumped by 13728 bps to 206416.67% in 2025, then sank by 92 bps to 16376.62% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 16376.62%, 206416.67%, and 112636.36% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 81.93% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 66.31% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 71.88% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 87.65% |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 74.24% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 68.16% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 79.24% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -51.69% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 73.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 87.65% |
| Dec 31, 2025 | 85.19% |
| Sep 30, 2025 | 86.25% |
| Jun 30, 2025 | 86.87% |
| Mar 31, 2025 | 88.13% |
| Dec 31, 2024 | 91.05% |
| Sep 30, 2024 | 80.98% |
| Jun 30, 2024 | 86.37% |
| Mar 31, 2024 | 85.91% |
| Dec 31, 2023 | 85.81% |
| Sep 30, 2023 | 85.29% |
| Jun 30, 2023 | 86.90% |
| Mar 31, 2023 | 84.93% |
| Dec 31, 2022 | 74.12% |
| Sep 30, 2022 | 72.85% |
| Jun 30, 2022 | 73.12% |
| Mar 31, 2022 | 69.17% |
| Dec 31, 2021 | 64.24% |
| Sep 30, 2021 | 62.71% |
| Jun 30, 2021 | 74.94% |